Replicel Announces Update on Filing of Annual Financial Statements and MD&A Due to COVID-19 Related Delays

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学
Published on: July 27, 2020

VANCOUVER, BC – July 27, 2020 – Replicel Life Sciences Inc. (the “Company” or “Replicel”)is pleased to provide this update on the status of the audit of its consolidated annual financial statements for the year ended December 31, 2019 (the “2019 Financial Statements”), the management discussion and analysis and the related officer certifications. As previously announced, the British Columbia Securities Commission issued a management cease trade order on June 17, 2020 because the Company was unable to timely file the 2019 Financial Statements, and the Company is filing this status update in accordance with National Policy 12-203, Management Cease Trade Orders, which requires bi-weekly updates by way of news releases.

The Company expects to file the 2019 Financial Statements and related documents on July 31, 2020.

For more information, please contact:

Telephone: 604-248-8693 / [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements and information that involve various risks and uncertainties regarding future events, including, but not limited to, statements regarding the estimated date of filing of the Company’s 2019 Financial Statements and related documents.

These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the COVID-19 pandemic and associated consequences will result in additional delays in the preparation of the Company’s 2019 Financial Statements and related documents and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2018 and other periodic reports filed from time-totime with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Biotechnology Life Science